The Supreme Court appeared skeptical of a lower court ruling that would restrict access to medication abortion Tuesday, during oral arguments in two cases challenging the Food and Drug Administration regulation of the drug mifepristone.
Most of the justices aired concerns about the U.S. Court of Appeals for the 5th Circuit’s decision in a challenge to the FDA’s loosening of prescribing rules in 2016 and 2021 by anti-abortion medical groups and four physicians.
And some key justices, including some conservatives on the court, focused on whether the case should be in court at all or why the moral objections of a handful of doctors should lead to a court ruling that would limit access in all 50 states.
